Pound for Pound: 3 Buzzworthy Drug Stocks Worth Their Weight in Gold
Weight-loss drugs are taking the U.S. by storm. JPMorgan Chase (NYSE: JPM ) is forecasting that the market for weight-loss medications could reach $100 billion in annual sales.
Investors May Not Have Seen the Best From Eli Lilly Stock Yet. Here's Why.
Eli Lilly's type 2 diabetes treatment, called Mounjaro, is helping fuel new growth for the company. In addition to diabetes, Eli Lilly is looking to fast track Mounjaro for weight-loss approval by ...
Analysis: Wegovy launch in UK may underline Novo's need to get ahead of Lilly
Novo Nordisk's decision to launch its weight-loss drug Wegovy in Britain last week despite severe supply constraints may partly have been motivated by a desire to get ahead of rival Eli Lilly's own...
Big pharma's blockbuster obesity drug battle is just getting started, and it's headed for $100 billion
As Novo Nordisk and Eli Lilly duke it out in the weight-loss drug market with Ozempic, Wegovy and Mounjaro, drug company competitors plan to join the fray.
Only 2 Mega-Cap Monster Stocks Have Risen in Each of the Last 5 Years: Are They Buys Now?
Of the more than 40 current mega-cap stocks, only two have generated positive returns in each of the last five years. One is a highly diversified conglomerate, while the other is a fast-growing pha...
Lilly's diabetes drug gains backing of UK watchdog -Bloomberg News
Eli Lilly's drug Mounjaro has won the backing of Britain's drug cost-effectiveness watchdog as a diabetes treatment, Bloomberg News reported on Thursday.
Mizuho's Jared Holz reacts to JPMorgan's huge obesity drug call
Jared Holz, Mizuho, joins 'Fast Money' to talk JPMorgans $100 billion call on weight loss drugs.
Weight-Loss Drug Market Can Hit $100 Billion, J.P. Morgan Says.
Eli Lilly and Denmark's Novo Nordisk are expected to roughly split the market for weight-loss drugs, both as diabetes and obesity treatments.
1 Weight-Loss Stock That's Been a Hotter Buy Than Eli Lilly and Novo Nordisk This Year
Shares of WW International have been soaring this year as a result of some promising drugs. Even companies that aren't involved in making the drugs have piggybacked on the hype.
Here are the 13 stocks Jim Cramer is watching, including Eli Lilly, McDonald's
Here are some of the tickers on my radar for Thursday, Sept. 7, taken directly from my reporter's notebook.
3 Nasdaq Stocks to Sell in September Before They Crash & Burn
Due to what could be an unsustainable rally for equities, you may be looking for Nasdaq stocks to sell now. We've had an incredible run this year, but there are some additional indiciations that ou...
Here's 1 Stock That Could Join Apple and Amazon in the $1 Trillion Club That You Might Have Overlooked
Unlike the current five stocks with $1 trillion market caps, AI isn't a major factor for this contender. Instead, its fortunes rely largely on treating diabetes, obesity, and Alzheimer's disease.
Novo Nordisk Is Now Europe's Biggest Company, Driven by Weight-Loss Drug. How Eli Lilly Could Benefit.
The pharma company's Wegovy medication helps it overtake luxury goods maker LVMH, with a market value of around $420 billion.
The 3 Most Promising Pharma Stocks to Own Now
It is remarkable that day after day there are pharmaceutical companies working hard, researching and developing high-tech medicines for the improvement of human health and the treatment of severe d...
What the medicare decision means for pharma stocks
Jared Holz, Mizuho, joins 'Fast Money' to talk the Biden Administration unveiling the first 10 drugs subject to medicare price negotiations and how pharma stocks are responding.
Related Companies